KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Historic Intangibles for Royalty Pharma (RPRX) over the last 3 years, with Q4 2021 value amounting to $5.7 million.

  • Royalty Pharma's Intangibles fell 8022.05% to $5.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $5.7 million, marking a year-over-year decrease of 8022.05%. This contributed to the annual value of $5.7 million for FY2021, which is 8022.05% down from last year.
  • Per Royalty Pharma's latest filing, its Intangibles stood at $5.7 million for Q4 2021, which was down 8022.05% from $11.5 million recorded in Q3 2021.
  • In the past 5 years, Royalty Pharma's Intangibles ranged from a high of $51.7 million in Q4 2019 and a low of $5.7 million during Q4 2021
  • Over the past 3 years, Royalty Pharma's median Intangibles value was $25.8 million (recorded in 2020), while the average stood at $26.6 million.
  • In the last 5 years, Royalty Pharma's Intangibles plummeted by 4457.89% in 2020 and then plummeted by 8022.05% in 2021.
  • Over the past 3 years, Royalty Pharma's Intangibles (Quarter) stood at $51.7 million in 2019, then crashed by 44.58% to $28.7 million in 2020, then plummeted by 80.22% to $5.7 million in 2021.
  • Its Intangibles stands at $5.7 million for Q4 2021, versus $11.5 million for Q3 2021 and $17.3 million for Q2 2021.